{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T15:06:50Z","timestamp":1792076810997,"version":"4.4.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100009620","name":"Science and Technology Department of Gansu Province","doi-asserted-by":"publisher","award":["212102310127"],"award-info":[{"award-number":["212102310127"]}],"id":[{"id":"10.13039\/501100009620","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009620","name":"Science and Technology Department of Gansu Province","doi-asserted-by":"publisher","award":["YXKC2020059"],"award-info":[{"award-number":["YXKC2020059"]}],"id":[{"id":"10.13039\/501100009620","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Biological Macromolecules"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.ijbiomac.2021.03.112","type":"journal-article","created":{"date-parts":[[2021,3,23]],"date-time":"2021-03-23T01:37:31Z","timestamp":1616463451000},"page":"605-611","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase"],"prefix":"10.1016","volume":"181","author":[{"given":"Suliman","family":"Khan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farnoosh","family":"Attar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samir Haj","family":"Bloukh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majid","family":"Sharifi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal","family":"Nabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rizwan Hasan","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mojtaba","family":"Falahati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijbiomac.2021.03.112_bb0005","article-title":"Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2): an update","volume":"12","author":"Pal","year":"2020","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.03.112_bb0010","doi-asserted-by":"crossref","first-page":"153","DOI":"10.3390\/vaccines8020153","article-title":"Progress and prospects on vaccine development against SARS-CoV-2","volume":"8","author":"Zhang","year":"2020","journal-title":"Vaccines"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0015","first-page":"1","article-title":"The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak","volume":"1","author":"Rothan","year":"2020","journal-title":"J. Autoimmun."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.03.112_bb0020","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/ije\/dyaa033","article-title":"The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?","volume":"49","author":"Peeri","year":"2020","journal-title":"Int. J. Epidemiol."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0025","doi-asserted-by":"crossref","unstructured":"M. Sharifi, A. Hasan, A. Taghizadeh, S. Haghighat, F. Attar, S.H. Bloukh, Z. Edis, M. Xue, S. Khan, M. Falahati, Rapid diagnostics of coronavirus disease 2019 in early stages using nanobiosensors: challenges and opportunities, Talanta (2020) 121704.","DOI":"10.1016\/j.talanta.2020.121704"},{"issue":"Suppl 2","key":"10.1016\/j.ijbiomac.2021.03.112_bb0030","first-page":"1","article-title":"Novel coronavirus COVID-19: an overview for emergency clinicians, Emergency Medicine Practice","volume":"22","author":"Giwa","year":"2020","journal-title":"COVID-19 FEBRUARY"},{"issue":"4","key":"10.1016\/j.ijbiomac.2021.03.112_bb0035","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.jinf.2020.02.017","article-title":"Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2","volume":"80","author":"Xu","year":"2020","journal-title":"J. Infect."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0040","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40249-020-00646-x","article-title":"Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review","volume":"9","author":"Adhikari","year":"2020","journal-title":"Infectious Diseases of Poverty"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0045","first-page":"1","article-title":"Analysis clinical features of COVID-19 infection in secondary epidemic area and report potential biomarkers in evaluation","volume":"1","author":"Ji","year":"2020","journal-title":"medRxiv"},{"issue":"13","key":"10.1016\/j.ijbiomac.2021.03.112_bb0050","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jama.2020.2342","article-title":"Preparing for the most critically ill patients with COVID-19: the potential role of extracorporeal membrane oxygenation","volume":"323","author":"MacLaren","year":"2020","journal-title":"Jama"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0055","series-title":"Clinical Management of Patients With Moderate to Severe COVID-19-Interim Guidance","author":"Tamblyn","year":"2020"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0060","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic","volume":"38","author":"Prompetchara","year":"2020","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.clim.2020.108393","article-title":"The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the experience of clinical immunologists from China","volume":"214","author":"Zhang","year":"2020","journal-title":"Clin. Immunol."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0070","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/S1473-3099(20)30132-8","article-title":"COVID-19: combining antiviral and anti-inflammatory treatments","volume":"20","author":"Stebbing","year":"2020","journal-title":"Lancet Infect. Dis."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0075","doi-asserted-by":"crossref","first-page":"58","DOI":"10.5582\/ddt.2020.01012","article-title":"Discovering drugs to treat coronavirus disease 2019 (COVID-19)","volume":"14","author":"Dong","year":"2020","journal-title":"Drug Discoveries & Therapeutics"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40779-020-00240-0","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak\u2013an update on the status","volume":"7","author":"Guo","year":"2020","journal-title":"Military Medical Research"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0085","first-page":"1","article-title":"Structure-based drug design, virtual screening and high-throughput screening rapidly identify antiviral leads targeting COVID-19","volume":"1","author":"Jin","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0090","series-title":"In Silico Identification and Docking-based Drug Repurposing against the Main Protease of SARS-CoV-2, Causative Agent of COVID-19","author":"Kumar","year":"2020"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0095","first-page":"19","article-title":"A mini-review on the current COVID-19 treatments","volume":"3","author":"Shafiee","year":"2020","journal-title":"Chemical Review and Letters"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0100","doi-asserted-by":"crossref","first-page":"109581","DOI":"10.1109\/ACCESS.2020.3001973","article-title":"Artificial intelligence and COVID-19: deep learning approaches for diagnosis and treatment","volume":"8","author":"Jamshidi","year":"2020","journal-title":"IEEE Access"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0105","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173467","article-title":"What to expect from different drugs used in the treatment of COVID-19: a study on applications and in vivo and in vitro results","volume":"887","author":"Marcolino","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.03.112_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105955","article-title":"The epidemiology, diagnosis and treatment of COVID-19","volume":"55","author":"Zhai","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"issue":"21","key":"10.1016\/j.ijbiomac.2021.03.112_bb0115","doi-asserted-by":"crossref","first-page":"4813","DOI":"10.1111\/bph.15072","article-title":"Current pharmacological treatments for COVID-19: what\u2019s next?","volume":"177","author":"Scavone","year":"2020","journal-title":"Br. J. Pharmacol."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.03.112_bb0120","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China","volume":"21","author":"Liang","year":"2020","journal-title":"The Lancet Oncology"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0125","article-title":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series","volume":"368","author":"Xu","year":"2020","journal-title":"Bmj"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0130","doi-asserted-by":"crossref","unstructured":"K. Dick, K.K. Biggar, J.R. Green, Computational prediction of the comprehensive SARS-CoV-2 vs. human interactome to guide the design of therapeutics, BioRxiv (2020).","DOI":"10.1101\/2020.03.29.014381"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0135","series-title":"Repurposing Therapeutics for Covid-19: Supercomputer-based Docking to the SARS-CoV-2 Viral Spike Protein and Viral Spike Protein-Human ace2 Interface","author":"Smith","year":"2020"},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.03.112_bb0140","doi-asserted-by":"crossref","first-page":"105938","DOI":"10.1016\/j.ijantimicag.2020.105938","article-title":"New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?","volume":"55","author":"Devaux","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0145","series-title":"Focusing on the Unfolded Protein Response and Autophagy Related Pathways to Reposition Common Approved Drugs Against COVID-19","author":"Nabirotchkin","year":"2020"},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.03.112_bb0150","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/jmv.25707","article-title":"Potential interventions for novel coronavirus in China: a systemic review","volume":"92","author":"Zhang","year":"2020","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0155","series-title":"Advanced Bioinformatics Rapidly Identifies Existing Therapeutics for Patients With Coronavirus Disease-2019 (COVID-19)","author":"Kim","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0160","first-page":"1","article-title":"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China","volume":"1","author":"Li","year":"2020","journal-title":"medRxiv"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0165","first-page":"2020020407","article-title":"Clinical pathology of critical patient with novel coronavirus pneumonia (COVID-19)","author":"Luo","year":"2020","journal-title":"Pathology & Pathobiology"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0170","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2008.05.006","article-title":"New treatment options for HIV salvage patients: an overview of second generation PIs, NNRTIs, integrase inhibitors and CCR5 antagonists","volume":"57","author":"Hughes","year":"2008","journal-title":"J. Infect."},{"issue":"4","key":"10.1016\/j.ijbiomac.2021.03.112_bb0175","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a007161","article-title":"HIV-1 antiretroviral drug therapy","volume":"2","author":"Arts","year":"2012","journal-title":"Cold Spring Harbor Perspectives in Medicine"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0180","first-page":"1","article-title":"Development of remdesivir repositioning as a nucleotide analog against COVID-19 RNA dependent RNA polymerase","author":"Babadaei","year":"2020","journal-title":"Journal of Biomolecular Structure and Dynamics (just-accepted)"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0185","first-page":"1","article-title":"Fragment tailoring strategy to design novel chemical entities as potential binders of novel corona virus main protease","author":"Choudhury","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"issue":"47","key":"10.1016\/j.ijbiomac.2021.03.112_bb0190","doi-asserted-by":"crossref","first-page":"16156","DOI":"10.1074\/jbc.AC120.015720","article-title":"Template-dependent inhibition of coronavirus RNA-dependent RNA polymerase by remdesivir reveals a second mechanism of action","volume":"295","author":"Tchesnokov","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0195","first-page":"1","article-title":"Structural analysis, virtual screening and molecular simulation to identify potential inhibitors targeting 2\u2019-O-ribose methyltransferase of SARS-CoV-2 coronavirus","author":"Jiang","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104793","article-title":"Remdesivir and SARS-CoV-2: structural requirements at both nsp12 RdRp and nsp14 exonuclease active-sites","volume":"178","author":"Shannon","year":"2020","journal-title":"Antivir. Res."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.03.112_bb0205","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41423-020-0400-4","article-title":"Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine","volume":"17","author":"Tai","year":"2020","journal-title":"Cellular & Molecular Immunology"},{"issue":"14","key":"10.1016\/j.ijbiomac.2021.03.112_bb0210","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.00635-20","article-title":"Design of potent membrane fusion inhibitors against SARS-CoV-2, an emerging coronavirus with high fusogenic activity","volume":"94","author":"Zhu","year":"2020","journal-title":"J. Virol."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0215","first-page":"1","article-title":"Recent advances in the discovery of potent RNA-dependent RNA-polymerase (RdRp) inhibitors targeting viruses","volume":"1","author":"Kumar","year":"2021","journal-title":"RSC Medicinal Chemistry"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0220","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1002\/jmv.26264","article-title":"RNA-dependent RNA polymerase of SARS-CoV-2 as a therapeutic target","volume":"93","author":"Wang","year":"2021","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0225","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.3389\/fmicb.2019.01280","article-title":"Calicivirus RNA-dependent RNA polymerases: evolution, structure, protein dynamics, and function","volume":"10","author":"Smertina","year":"2019","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0230","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.coviro.2019.04.002","article-title":"Nucleoside analogues for the treatment of coronavirus infections","volume":"35","author":"Pruijssers","year":"2019","journal-title":"Current Opinion in Virology"},{"issue":"396","key":"10.1016\/j.ijbiomac.2021.03.112_bb0235","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aal3653","article-title":"Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses","volume":"9","author":"Sheahan","year":"2017","journal-title":"Sci. Transl. Med."},{"issue":"8","key":"10.1016\/j.ijbiomac.2021.03.112_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003565","article-title":"Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics","volume":"9","author":"Smith","year":"2013","journal-title":"PLoS Pathog."},{"issue":"2\u20133","key":"10.1016\/j.ijbiomac.2021.03.112_bb0245","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.antiviral.2005.01.003","article-title":"Inhibitory effect of mizoribine and ribavirin on the replication of severe acute respiratory syndrome (SARS)-associated coronavirus","volume":"66","author":"Saijo","year":"2005","journal-title":"Antivir. Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0250","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1592\/phco.21.1.11.34439","article-title":"Phosphorylation of nucleoside analog antiretrovirals: a review for clinicians","volume":"21","author":"Stein","year":"2001","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0255","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1080\/10408347.2019.1570462","article-title":"Current standing and technical guidance on intracellular drug quantification: a new site specific bioavailability prediction approach","volume":"50","author":"Jadav","year":"2020","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0260","series-title":"Evolution of HCV NS5B Nucleoside and Nucleotide Inhibitors, HCV: The Journey From Discovery to a Cure","first-page":"117","volume":"vol. I","author":"Cho","year":"2019"},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.03.112_bb0265","doi-asserted-by":"crossref","first-page":"e00674","DOI":"10.1002\/prp2.674","article-title":"Nucleotide analogues as inhibitors of SARS-CoV polymerase","volume":"8","author":"Ju","year":"2020","journal-title":"Pharmacol. Res. Perspect."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104857","article-title":"A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19","volume":"180","author":"Jockusch","year":"2020","journal-title":"Antivir. Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2021.03.112_bb0275","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, a key drug target for COVID-19","volume":"19","author":"Chien","year":"2020","journal-title":"J. Proteome Res."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-020-18463-z","article-title":"Rapid incorporation of Favipiravir by the fast and permissive viral RNA polymerase complex results in SARS-CoV-2 lethal mutagenesis","volume":"11","author":"Shannon","year":"2020","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.03.112_bb0285","doi-asserted-by":"crossref","DOI":"10.1128\/mSystems.00297-20","article-title":"Repurposing didanosine as a potential treatment for COVID-19 using single-cell RNA sequencing data","volume":"5","author":"Alakwaa","year":"2020","journal-title":"Msystems"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0290","unstructured":"F. Hu, J. Jiang, P. Yin, Prediction of potential commercially inhibitors against SARS-CoV-2 by multi-task deep model, arXiv preprint arXiv:2003.00728 (2020)."},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0295","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jcv.2004.03.003","article-title":"In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds","volume":"31","author":"Chen","year":"2004","journal-title":"J. Clin. Virol."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.03.112_bb0300","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.jinf.2013.09.029","article-title":"Broad-spectrum antivirals for the emerging Middle East respiratory syndrome coronavirus","volume":"67","author":"Chan","year":"2013","journal-title":"J. Infect."},{"issue":"15","key":"10.1016\/j.ijbiomac.2021.03.112_bb0305","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1016\/j.bmcl.2015.05.039","article-title":"Design, synthesis and evaluation of a series of acyclic fleximer nucleoside analogues with anti-coronavirus activity","volume":"25","author":"Peters","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.03.112_bb0310","doi-asserted-by":"crossref","DOI":"10.1128\/mBio.00221-18","article-title":"Coronavirus susceptibility to the antiviral remdesivir (GS-5734) is mediated by the viral polymerase and the proofreading exoribonuclease","volume":"9","author":"Agostini","year":"2018","journal-title":"MBio"},{"issue":"1","key":"10.1016\/j.ijbiomac.2021.03.112_bb0315","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-019-13940-6","article-title":"Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV","volume":"11","author":"Sheahan","year":"2020","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.03.112_bb0320","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1177\/095632020601700505","article-title":"Evaluation of immunomodulators, interferons and known in vitro SARS-coV inhibitors for inhibition of SARS-coV replication in BALB\/c mice","volume":"17","author":"Barnard","year":"2006","journal-title":"Antivir. Chem. Chemother."},{"issue":"6","key":"10.1016\/j.ijbiomac.2021.03.112_bb0325","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1128\/AAC.01598-05","article-title":"Inhibition of human coronavirus NL63 infection at early stages of the replication cycle","volume":"50","author":"Pyrc","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"issue":"8","key":"10.1016\/j.ijbiomac.2021.03.112_bb0330","doi-asserted-by":"crossref","first-page":"4885","DOI":"10.1128\/AAC.03036-14","article-title":"Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection","volume":"58","author":"Dyall","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0335","doi-asserted-by":"crossref","first-page":"117592","DOI":"10.1016\/j.lfs.2020.117592","article-title":"Ribavirin, Remdesivir, Sofosbuvir, Galidesivir, and Tenofovir against SARS-CoV-2 RNA dependent RNA polymerase (RdRp): a molecular docking study","volume":"253","author":"Elfiky","year":"2020","journal-title":"Life Sci."},{"issue":"32","key":"10.1016\/j.ijbiomac.2021.03.112_bb0340","doi-asserted-by":"crossref","first-page":"6955","DOI":"10.1021\/acs.jpcb.0c04198","article-title":"Structural basis of potential binding mechanism of remdesivir to SARS-CoV-2 RNA dependent RNA polymerase","volume":"124","author":"Zhang","year":"2020","journal-title":"J. Phys. Chem. B"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0345","doi-asserted-by":"crossref","unstructured":"M. Arba, S.T. Wahyudi, D.J. Brunt, N. Paradis, C. Wu, Mechanistic insight on the remdesivir binding to RNA-dependent RNA polymerase (RdRp) of SARS-cov-2, Comput. Biol. Med. (2020) 104156.","DOI":"10.1016\/j.compbiomed.2020.104156"},{"issue":"45","key":"10.1016\/j.ijbiomac.2021.03.112_bb0350","doi-asserted-by":"crossref","first-page":"26792","DOI":"10.1039\/D0RA04743K","article-title":"Remdesivir-bound and ligand-free simulations reveal the probable mechanism of inhibiting the RNA dependent RNA polymerase of severe acute respiratory syndrome coronavirus 2","volume":"10","author":"Koulgi","year":"2020","journal-title":"RSC Adv."},{"issue":"47","key":"10.1016\/j.ijbiomac.2021.03.112_bb0355","doi-asserted-by":"crossref","first-page":"10641","DOI":"10.1021\/acs.jpcb.0c06747","article-title":"Revealing the inhibition mechanism of RNA-dependent RNA polymerase (RdRp) of SARS-CoV-2 by Remdesivir and nucleotide analogues: a molecular dynamics simulation study","volume":"124","author":"Wakchaure","year":"2020","journal-title":"J. Phys. Chem. B"},{"issue":"20","key":"10.1016\/j.ijbiomac.2021.03.112_bb0360","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1074\/jbc.RA120.013679","article-title":"Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency","volume":"295","author":"Gordon","year":"2020","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0365","series-title":"FDA-approved Pralatrexate Identified by Virtual Drug Screening Inhibits SARS-CoV-2 Replication In Vitro","author":"Zhang","year":"2020"},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0370","doi-asserted-by":"crossref","unstructured":"M. Chien, T.K. Anderson, S. Jockusch, C. Tao, S. Kumar, X. Li, J.J. Russo, R. Kirchdoerfer, J. Ju, Nucleotide analogues as inhibitors of SARS-CoV-2 polymerase, bioRxiv (2020).","DOI":"10.1101\/2020.03.18.997585"},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.03.112_bb0375","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1111\/cts.12827","article-title":"Pharmacokinetics of Favipiravir in critically ill patients with COVID-19","volume":"13","author":"Irie","year":"2020","journal-title":"Clinical and Translational Science"},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.03.112_bb0380","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1002\/jmv.26488","article-title":"Tolerability of favipiravir therapy in critically ill patients with COVID-19: a report of four cases","volume":"93","author":"Dauby","year":"2021","journal-title":"J. Med. Virol."},{"issue":"11","key":"10.1016\/j.ijbiomac.2021.03.112_bb0385","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1093\/jac\/dkaa334","article-title":"Sofosbuvir and daclatasvir compared with standard of care in the treatment of patients admitted to hospital with moderate or severe coronavirus infection (COVID-19): a randomized controlled trial","volume":"75","author":"Sadeghi","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"11","key":"10.1016\/j.ijbiomac.2021.03.112_bb0390","doi-asserted-by":"crossref","first-page":"3373","DOI":"10.1093\/jac\/dkaa332","article-title":"Evaluation of the efficacy of sofosbuvir plus daclatasvir in combination with ribavirin for hospitalized COVID-19 patients with moderate disease compared with standard care: a single-centre, randomized controlled trial","volume":"75","author":"Abbaspour Kasgari","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.03.112_bb0395","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jac\/dkaa501","article-title":"Sofosbuvir and daclatasvir for the treatment of COVID-19 outpatients: a double-blind, randomized controlled trial","volume":"76","author":"Roozbeh","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"issue":"10238","key":"10.1016\/j.ijbiomac.2021.03.112_bb0400","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(20)31042-4","article-title":"Triple combination of interferon beta-1b, lopinavir\u2013ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial","volume":"395","author":"Hung","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.ijbiomac.2021.03.112_bb0405","doi-asserted-by":"crossref","first-page":"3366","DOI":"10.1093\/jac\/dkaa331","article-title":"The impact of sofosbuvir\/daclatasvir or ribavirin in patients with severe COVID-19","volume":"75","author":"Eslami","year":"2020","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijbiomac.2021.03.112_bb0410","first-page":"e13792","article-title":"Can Tenofovir diphosphate be a candidate drug for Sars-Cov2? First clinical perspective","author":"Kutlu","year":"2021","journal-title":"Int. J. Clin. Pract."},{"issue":"2","key":"10.1016\/j.ijbiomac.2021.03.112_bb0415","first-page":"118","article-title":"Treatments for COVID-19: emerging drugs against the coronavirus","volume":"91","author":"Pot\u00ec","year":"2020","journal-title":"Acta Bio Medica: Atenei Parmensis"},{"issue":"5","key":"10.1016\/j.ijbiomac.2021.03.112_bb0420","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/phar.2398","article-title":"Review of emerging pharmacotherapy for the treatment of coronavirus disease 2019","volume":"40","author":"Barlow","year":"2020","journal-title":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"},{"issue":"3","key":"10.1016\/j.ijbiomac.2021.03.112_bb0425","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-020-0282-0","article-title":"Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro","volume":"30","author":"Wang","year":"2020","journal-title":"Cell Res."},{"issue":"11","key":"10.1016\/j.ijbiomac.2021.03.112_bb0430","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1001\/jama.2020.16349","article-title":"Effect of remdesivir vs standard care on clinical status at 11 days in patients with moderate COVID-19: a randomized clinical trial","volume":"324","author":"Spinner","year":"2020","journal-title":"Jama"}],"container-title":["International Journal of Biological Macromolecules"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813021006474?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0141813021006474?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T08:53:16Z","timestamp":1758876796000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0141813021006474"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":86,"alternative-id":["S0141813021006474"],"URL":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.03.112","relation":{},"ISSN":["0141-8130"],"issn-type":[{"value":"0141-8130","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A review on the interaction of nucleoside analogues with SARS-CoV-2 RNA dependent RNA polymerase","name":"articletitle","label":"Article Title"},{"value":"International Journal of Biological Macromolecules","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijbiomac.2021.03.112","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}